Tower Research Capital LLC TRC Increases Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Tower Research Capital LLC TRC raised its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 102.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,489 shares of the medical device company's stock after acquiring an additional 6,838 shares during the period. Tower Research Capital LLC TRC's holdings in Cooper Companies were worth $1,240,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Byrne Asset Management LLC purchased a new position in Cooper Companies during the 4th quarter valued at about $33,000. OFI Invest Asset Management acquired a new position in shares of Cooper Companies during the fourth quarter worth $34,000. New Age Alpha Advisors LLC purchased a new position in Cooper Companies in the fourth quarter valued at $38,000. Covestor Ltd raised its stake in Cooper Companies by 35.5% in the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after buying an additional 120 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new stake in Cooper Companies during the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

Cooper Companies Trading Down 1.6 %

Shares of COO stock traded down $1.29 on Wednesday, reaching $80.94. 332,821 shares of the stock were exchanged, compared to its average volume of 1,419,223. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The stock has a market cap of $16.19 billion, a P/E ratio of 41.39, a price-to-earnings-growth ratio of 2.25 and a beta of 1.01. The firm has a 50 day moving average of $81.91 and a two-hundred day moving average of $92.34. The Cooper Companies, Inc. has a 1-year low of $69.81 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. On average, research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. BNP Paribas raised Cooper Companies to a "hold" rating in a report on Thursday, March 13th. Robert W. Baird lowered their target price on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a report on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a report on Friday, March 7th. Stifel Nicolaus decreased their price objective on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Finally, Piper Sandler restated an "overweight" rating and issued a $115.00 target price (down from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $110.25.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.